Document is current
Any future updates will be listed below
-
Authors
Idrees, Thaer https://orcid.org/0000-0001-9036-995X
Castro-Revoredo, Iris
Dhatariya, Ketan K.
Hernandez, Lucas
Umpierrez, Guillermo E. https://orcid.org/0000-0002-3252-5026
- License Information
-
More Information
Article History
Accepted: 12 July 2025
First Online: 4 August 2025
Change Date: 13 August 2025
Change Type: Update
Change Details: In the version of the article initially published, in Table 1, in the “AACE–ADA” row, both instances of “target glucose level of 7.8–10.0 mmol/l (100–180 mg/dl)” should have read “target glucose level of 7.8–10.0 mmol/l (140–180 mg/dl)” and have now been corrected in the HTML and PDF versions of the article.
Competing interests
: T.I. has received research support (paid to Emory University) from AbbVie. G.E.U. has received research support (paid to Emory University) from Bayer, Abbott, Dexcom and Corcept, and has served as a member of advisory boards for Dexcom, Mankind, Glucotrack, Corcept and GlyCare. K.K.D. has received honoraria for travel, advisory boards and speaker fees from Abbott Diabetes, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Menarini and Sanofi Diabetes. I.C.-R. and L.H. declare no competing interests.
